We performed a phase III trial to determine whether induction therapy with cytarabine and amonafide L-malate , a DNA intercalator and non-ATP-dependent topoisomerase II inhibitor that evades drug resistance mechanisms , yielded a superior complete remission rate than standard therapy with cytarabine and daunorubicin in sAML .